Memory and Aging Center Grand Rounds: Overall Impact of Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Date
UCSF Weill Institute for Neurosciences
Memory and Aging Center
Click here to register on Zoom or attend in person in Rock Hall Pottruck Auditorium (RH 102)
|
Learning Objectives
|
|
|
Disclosures |
|
Planners: Bruce L. Miller, MD; Howard J. Rosen, MD; Andrew Breithaupt, MD; and Eleanor O’Brien have stated they have no relationships to disclose. Speaker: Michael Weiner, MD, has disclosed the following relationships: editorial boards for Alzheimer’s & Dementia and the Journal for Prevention of Alzheimer’s Disease; advisory boards for Acumen Pharmaceutical, Alzheon, Inc., Cerecin, Merck Sharp & Dohme Corp., and NC Registry for Brain Health; the USC ACTC grant which receives funding from Eisai for the AHEAD study; consulting to Boxer Capital, LLC, Cerecin, Inc., Clario, Dementia Society of Japan, Eisai, Guidepoint, Health and Wellness Partners, Indiana University, LCN Consulting, Merck Sharp & Dohme Corp., NC Registry for Brain Health, Prova Education, T3D Therapeutics, University of Southern California (USC), and WebMD; speaker/lecturer for China Association for Alzheimer’s Disease (CAAD) and Taipei Medical University, as well as a speaker/lecturer with academic travel funding provided by: AD/PD Congress, Cleveland Clinic, CTAD Congress, Foundation of Learning; Health Society (Japan), INSPIRE Project; U. Toulouse, Japan Society for Dementia Research, and Korean Dementia Society, Merck Sharp & Dohme Corp., National Center for Geriatrics and Gerontology (NCGG; Japan), University of Southern California (USC). He holds stock options with Alzheon, Inc., Alzeca, ALZPath, Inc., and Anven. He has received support for his research from the following funding sources: National Institutes of Health (NIH)/NINDS/National Institute on Aging (NIA), Department of Defense (DOD), California Department of Public Health (CDPH), University of Michigan, Siemens, Biogen, Hillblom Foundation, Alzheimer’s Association, Johnson & Johnson, Kevin and Connie Shanahan, GE, VUmc, Australian Catholic University (HBI-BHR), The Stroke Foundation, and the Veterans Administration. |
Type
Time Duration
UCSF Weill Institute for Neurosciences
Memory and Aging Center
Click here to register on Zoom or attend in person in Rock Hall Pottruck Auditorium (RH 102)
|
Learning Objectives
|
|
|
Disclosures |
|
Planners: Bruce L. Miller, MD; Howard J. Rosen, MD; Andrew Breithaupt, MD; and Eleanor O’Brien have stated they have no relationships to disclose. Speaker: Michael Weiner, MD, has disclosed the following relationships: editorial boards for Alzheimer’s & Dementia and the Journal for Prevention of Alzheimer’s Disease; advisory boards for Acumen Pharmaceutical, Alzheon, Inc., Cerecin, Merck Sharp & Dohme Corp., and NC Registry for Brain Health; the USC ACTC grant which receives funding from Eisai for the AHEAD study; consulting to Boxer Capital, LLC, Cerecin, Inc., Clario, Dementia Society of Japan, Eisai, Guidepoint, Health and Wellness Partners, Indiana University, LCN Consulting, Merck Sharp & Dohme Corp., NC Registry for Brain Health, Prova Education, T3D Therapeutics, University of Southern California (USC), and WebMD; speaker/lecturer for China Association for Alzheimer’s Disease (CAAD) and Taipei Medical University, as well as a speaker/lecturer with academic travel funding provided by: AD/PD Congress, Cleveland Clinic, CTAD Congress, Foundation of Learning; Health Society (Japan), INSPIRE Project; U. Toulouse, Japan Society for Dementia Research, and Korean Dementia Society, Merck Sharp & Dohme Corp., National Center for Geriatrics and Gerontology (NCGG; Japan), University of Southern California (USC). He holds stock options with Alzheon, Inc., Alzeca, ALZPath, Inc., and Anven. He has received support for his research from the following funding sources: National Institutes of Health (NIH)/NINDS/National Institute on Aging (NIA), Department of Defense (DOD), California Department of Public Health (CDPH), University of Michigan, Siemens, Biogen, Hillblom Foundation, Alzheimer’s Association, Johnson & Johnson, Kevin and Connie Shanahan, GE, VUmc, Australian Catholic University (HBI-BHR), The Stroke Foundation, and the Veterans Administration. |
Speakers
Overall Impact of Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Michael Weiner, MD, is a Professor in Residence in Radiology and Biomedical Imaging, Medicine, Psychiatry, and Neurology at the University of California, San Francisco. He is Principle Investigator of the Alzheimer's Disease Neuroimaging Initiative, which is the largest observational study in the world concerning Alzheimer's Disease. He is the former Director of the Center for Imaging of Neurodegenerative Diseases (CIND) at the San Francisco Veterans Affairs Medical Center. After graduating from Johns Hopkins University in 1961, he obtained his MD, from SUNY Upstate Medical Center in Syracuse, New York in 1965, and he completed his internship and residency in Medicine from Mt. Sinai Hospital in 1967. From 1967-1968, Dr. Weiner completed a residency and clinical fellowship in Metabolism at Yale-New Haven Medical Center. In 1970, he completed a research fellowship in Nephrology from Yale University School of Medicine and a research fellowship in Biochemistry from the University of Wisconsin Institute for Enzyme Research in 1972, followed by a joint appointment in the Department of Medicine, Renal Section from the University of Wisconsin Institute in 1972. In 1974 he became an Assistant Professor of Medicine (Nephrology) at Stanford University, and in 1980 he became an Associate Professor of Medicine (Nephrology) at UCSF. In 1983, he established the Magnetic Resonance Unit at the San Francisco VA Medical Center, which became the Center for Imaging of Neurodegenerative Diseases in 2000. In 1990, he became a Professor of Radiology, Medicine, Psychiatry, and Neurology at UCSF.